Scarica l'app Stockscreener
0.8816
0.34%
-0.0045
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Cardiff Oncology Inc Borsa (CRDF) Ultime notizie
Enterprise value to EBIT forward of Cardiff Oncology, Inc. – DUS:XE7C - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Cardiff Oncology (CRDF) asks investors to double authorized common shares - Stock Titan
Cardiff Oncology (CRDF) Holds Near $0.98 as Consolidation PersistsFibonacci Extension - Vinanet
CARDIFF ONCOLOGY, INC. : WILLIAM BLAIR CUTS TO MARKET PERFORM RATING - webull.com
Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE) and Cardiff Oncology (CRDF) - The Globe and Mail
CRDF Downgraded by William Blair -- Rating Changed to Market Per - GuruFocus
William Blair Downgrades Cardiff Oncology to Market Perform From Outperform - marketscreener.com
Piper Sandler Maintains Cardiff Oncology(CRDF.US) With Buy Rating, Maintains Target Price $6 - Moomoo
William Blair downgrades Cardiff Oncology stock rating on rights uncertainty - Investing.com
William Blair downgrades Cardiff Oncology stock rating on rights uncertainty By Investing.com - Investing.com Canada
Cardiff Oncology earnings missed by $0.02, revenue topped estimates - Investing.com Canada
Is Cardiff Oncology Inc (CRDF) Moving in the Right Direction Aft - GuruFocus
Cardiff Oncology: Q2 Earnings Snapshot - AOL.com
Cardiff Oncology Q2 operating expenses fall on lower R&D costs - TradingView
Cardiff Oncology (NASDAQ:CRDF) Releases Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update - The Manila Times
Cardiff Oncology (NASDAQ: CRDF) cuts R&D spend but flags going concern risk - Stock Titan
Cardiff Oncology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Cardiff Oncology Inc (CRDF) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cardiff Oncology, Inc. (NASDAQ:CRDF) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Cardiff Oncology (CRDF) Expected to Post Quarterly Earnings on Tuesday - MarketBeat
Cardiff Oncology Inc (CRDF) Valuation: PE, PB & Fair Value Analysis - TradingKey
BlackRock (CRDF holder) discloses 863,259 Cardiff Oncology shares in 13G/A - Stock Titan
CRDF|Cardiff Oncology Inc|Price:0.952|Chg%:+0.023 - TradingKey
Cardiff Oncology Inc (CRDF) Balance Sheet - TradingKey
CRDF|Cardiff Oncology Inc|Price:0.827|Chg%:-0.011 - TradingKey
Cardiff Oncology Inc (CRDF) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cardiff Oncology Inc (CRDF) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cardiff Oncology Inc (CRDF) Institutional Confidence - TradingKey
Cardiff Oncology, Inc. Revenue Breakdown – NASDAQ:CRDF - TradingView
Cardiff Oncology Inc (CRDF) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cardiff Oncology Inc (CRDF) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cardiff Oncology Inc (CRDF) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cardiff Oncology Inc (CRDF) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Cardiff Oncology Inc expected to post a loss of 16 cents a shareEarnings Preview - TradingView
Cardiff Oncology Inc (CRDF) Cash Flow - TradingKey
CRDF|Cardiff Oncology Inc|Price:0.831|Chg%:+0.004 - TradingKey
CRDF|Cardiff Oncology Inc|Price:0.845| - TradingKey
TradingKey - TradingKey
Cardiff Oncology, Inc. (CRDF) Q4 2023 Earnings ReportResults, Call & Slides - TipRanks
CRDF Q1 2026 Earnings: EPS Misses Estimates Amid Ongoing Pipeline DevelopmentEarnings Yield Spread - Vinanet
Cardiff Oncology completes $10 million financing transaction - TipRanks
Cardiff Oncology CEO Mani Mohindru buys $49,999 of common stock - Investing.com UK
Cardiff Oncology (CRDF) Proxy filing Summary - Quartr
Insider Buying: Mani Mohindru Acquires Shares of Cardiff Oncology Inc (CRDF) - GuruFocus
Cardiff Oncology CEO Mani Mohindru buys $49,999 of common stock By Investing.com - Investing.com Nigeria
Form 4 Cardiff Oncology Inc For: 16 July By Investing.com - Investing.com Nigeria
Cardiff Oncology Director Purchased Shares Worth Over $999K - TradingView
Cardiff Oncology Insider Bought Shares Worth $1,000,000, According to a Recent SEC Filing - marketscreener.com
Cardiff Oncology (CRDF) director buys 687,285 shares and warrants - Stock Titan
Cardiff Oncology (CRDF) CEO adds common shares and new warrants stake - Stock Titan
Cardiff Oncology Raises $10M for Onvansertib Regulatory Push - AllSci
Cardiff Oncology Announces $10 Million Registered Direct Offering to Advance Cancer Therapy Pipeline - Minichart
Cardiff Oncology Raises $10.05 Million in Registered Offering; Engages H.C. Wainwright - TradingView
Cardiff Oncology (Nasdaq: CRDF) closes $10.05M direct offering - Stock Titan
Cardiff Oncology (NASDAQ: CRDF) prices $10.05M share and warrant financing - Stock Titan
Cardiff Oncology announces $10M direct offering - MSN
Crude Oil Moves Lower; US Producer Prices Fall 0.3% In June - Sahm
Cardiff Oncology to Raise $10 Million in Share, Warrant Sale - Moomoo
Cardiff Oncology prices $10M registered direct offering - Investing.com UK
Cardiff Oncology prices $10M registered direct offering By Investing.com - Investing.com South Africa
Cardiff Oncology Announces $10 Million Registered Direct Offering to Strengthen Working Capital - Yahoo Finance
2.11%
0.45%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):